Investors in Tempus AI were allegedly misled about the company’s artificial intelligence health revenue, according to a securities class action lawsuit filed in June 2025. The complaint alleges that Tempus AI inflated its AI-related revenue figures and contract values in filings to the Securities and Exchange Commission, deceiving investors about the true scale and profitability of its core AI business. During 2024, Tempus AI reported only $12.4 million in AI-related revenue despite presenting itself as an artificial intelligence health company—a figure representing less than 2% of the company’s total reported revenue of $693.4 million. This significant gap between how the company portrayed its AI operations and the actual revenue generated from those operations forms the foundation of allegations that investors made decisions based on materially false or misleading information. The lawsuit accelerated after a critical report from short-seller Spruce Point Capital Management on May 28, 2025, which identified what it characterized as inflated contract values and questionable accounting practices.
Within hours of the report’s release, Tempus AI’s stock price collapsed 19.23%, dropping from $63.99 to $53.20 per share on what became known as a catastrophic trading day for the company. The class action, formally titled Shouse v. Tempus AI, Inc., was filed in U.S. District Court for the Northern District of Illinois on June 12, 2025, on behalf of investors who purchased Tempus AI securities during the period from August 6, 2024, through May 27, 2025. The case seeks approximately $50 million in damages and has since been consolidated with another lawsuit, Farrier et al v. Tempus AI, Inc., pending before the same court.
Table of Contents
- How Did Tempus AI Allegedly Inflate Its AI Revenue Claims?
- What Role Did Related-Party Transactions Play in Revenue Recognition?
- What Triggered the Stock Price Collapse and Subsequent Litigation?
- What Are Investors’ Legal Options if They Held Tempus AI Stock?
- What Additional Allegations Has Tempus AI Faced Beyond Revenue Claims?
- How Do Securities Fraud Cases Typically Proceed and Resolve?
- What Does the Tempus AI Case Reveal About Investment Risk and Due Diligence?
- Conclusion
How Did Tempus AI Allegedly Inflate Its AI Revenue Claims?
The central allegation in the lawsuit concerns how Tempus AI calculated and reported revenue from its artificial intelligence operations. According to the complaint, the company included $300 million in cumulative non-binding opt-ins in its Total Contract Value (TCV) calculations—a practice that significantly overstates the company’s actual contracted revenue. Non-binding opt-ins represent customer agreements that may be terminated without penalty, meaning they carry far less certainty than binding contracts. Yet by including them in TCV disclosures, plaintiffs argue the company created a misleading impression of the strength and stability of its AI health business. The inclusion of these non-binding arrangements inflated the apparent size of Tempus AI’s AI revenue pipeline by a factor that bears little relationship to actual monetized contracts.
Additionally, the complaint identifies $22.4 million in what it characterizes as “unlikely milestone payments” that were factored into revenue projections and financial presentations. Milestone payments—revenue contingent on the achievement of specific business targets or conditions—carry inherent uncertainty compared to revenue from services already delivered or standing contracts. By including payments deemed “unlikely” to materialize alongside more concrete revenue figures, the company allegedly presented a distorted picture of its financial trajectory to investors. The distinction matters enormously for investors evaluating whether to buy or hold Tempus AI shares. An investor reviewing financials that prominently feature milestone payments and non-binding commitments might conclude the company’s AI business was substantially larger and more established than the actual $12.4 million in realized AI revenue suggested.
What Role Did Related-Party Transactions Play in Revenue Recognition?
The lawsuit further alleges that Tempus AI entered into multiple contracts involving related-party deals and what it describes as self-funded commitments, raising questions about whether those revenues should have been recognized under standard accounting principles. A related-party transaction occurs when a company does business with an entity in which company insiders have a financial interest. These transactions require careful scrutiny under securities regulations because they can be used to artificially inflate revenue figures. For example, if Tempus AI made a contract with a company partially owned or controlled by Tempus AI executives or major shareholders, that arrangement warrants special disclosure and skepticism about whether it represents genuine arms-length business activity.
Self-funded commitments present a similar red flag. This term generally describes situations where a company essentially funds its own revenues by providing capital or other resources to a customer, which then uses those resources to pay the company back. The effect is circular: the company appears to generate revenue when in reality it has simply moved money from one pocket to another. Investors analyzing financial statements would typically assume that reported revenue reflects genuine economic activity where customers are paying for services from their own resources. The complaint suggests that by failing to adequately disclose and segregate related-party and self-funded arrangements, Tempus AI misrepresented the organic health and growth of its AI health business to the market.
What Triggered the Stock Price Collapse and Subsequent Litigation?
The immediate catalyst for both the stock price decline and the class action lawsuit was the May 28, 2025 release of a research report from Spruce Point Capital Management, an investment research firm known for detailed scrutiny of public companies. The report carried a “Strong Sell” rating and alleged that Tempus AI had engaged in aggressive and misleading accounting practices. Spruce Point’s analysis identified the inflated contract values and challenged how the company had recognized revenue from its AI health operations. Within the same trading day, investors rushed to exit their positions, triggering a market repricing that eliminated billions of dollars in shareholder value.
The timing of the report’s release and the stock market’s response created the legal conditions necessary for a securities class action to proceed. When a company makes allegedly misleading statements and the truth subsequently becomes known to the market—often through a negative report or earnings announcement—shareholders can claim they were harmed by the price decline. Class actions rely on demonstrating that investors would have paid a different price if they had known the truth about the company’s finances. Tempus AI’s 19.23% stock price drop in a single day provided statistical evidence that the market viewed Spruce Point’s revelations as material and significant. The consolidated lawsuits now pending in federal court include claims from investors who purchased shares during the class period and suffered losses when the stock repriced.
What Are Investors’ Legal Options if They Held Tempus AI Stock?
Investors who purchased Tempus AI securities between August 6, 2024, and May 27, 2025, may be eligible to join the class action lawsuit without filing a separate claim or taking any action. Class action lawsuits allow multiple injured parties to pursue claims collectively, which reduces litigation costs and administrative burdens compared to individual lawsuits. A purchaser need only demonstrate that they bought Tempus AI stock or other covered securities during the class period and held positions that lost value following the disclosure of the allegedly misleading financial information. The lawsuit’s current target of approximately $50 million in damages suggests that if successful, individual recoveries would depend on the size of each investor’s losses. The comparison between pursuing a class action versus initiating an independent lawsuit illustrates why class actions exist.
Filing a solo securities lawsuit against a public company requires retaining specialized securities counsel, navigating complex litigation procedures, and typically requires plaintiffs to post security for defendants’ attorneys’ fees. A class action consolidates these resources and spreads the cost across many claimants. However, there are tradeoffs: class members surrender individual control over settlement negotiations and case strategy. They become bound by decisions made by class representatives and their attorneys, whom the court oversees to ensure they act in the class’s interest. Investors who believe they have substantially larger losses might explore individual claims, but most affected shareholders find the class action mechanism more practical and cost-effective.
What Additional Allegations Has Tempus AI Faced Beyond Revenue Claims?
Beyond the revenue misrepresentation allegations, the lawsuit and related disclosures have raised concerns about Tempus AI’s handling of genetic information. The complaint references alleged violations of the Illinois Genetic Information Privacy Act regarding disclosures of genetic data to third parties. Genetic information requires heightened legal protection under both federal and state laws because of its sensitivity and unique characteristics. Unlike other personal data, genetic information reveals not only information about an individual but also about biological relatives.
Under Illinois law and the federal Genetic Information Nondiscrimination Act (GINA), companies must obtain proper consent before using or disclosing genetic data and must implement safeguards to prevent unauthorized access. The complaint’s mention of genetic information privacy violations adds a regulatory and legal compliance dimension to the fraud allegations surrounding revenue recognition. Additionally, some investors and analysts have questioned the historical track record of Tempus AI’s founder and CEO Eric Lefkofsky, pointing to his prior involvement in companies that faced financial controversies or scandals. While past business associations do not necessarily indicate current misconduct, they can inform investor due diligence and shareholder oversight. The combination of aggressive revenue recognition practices, related-party transactions, and concerns about genetic data handling creates a pattern of allegations that extends beyond simple accounting disagreements to encompass broader governance and compliance questions.
How Do Securities Fraud Cases Typically Proceed and Resolve?
Securities class actions follow a defined procedural path through federal court. After a complaint is filed, the defendants (in this case, Tempus AI and potentially certain officers or directors) file motions to dismiss, which the court evaluates to determine whether the complaint states a plausible claim. If the complaint survives dismissal, discovery begins—a period where both parties exchange documents, conduct depositions, and build evidence. Discovery in securities cases can be extensive, involving financial records, internal communications, and expert analyses. The consolidated Tempus AI cases, having been consolidated on April 15, 2026, are likely in early discovery phases as of mid-2026.
Settlement discussions often occur in parallel with litigation. Many securities class actions resolve through settlements in which defendants do not admit wrongdoing but agree to pay a sum to compensate harmed shareholders. Settlement amounts typically reflect the strength of the plaintiffs’ evidence, the potential damages exposure if the case were to proceed to trial, and the costs and risks of continued litigation. The approximate $50 million in damages sought represents a starting point for negotiations; final settlement figures often differ from initial damage calculations. Successful resolution of the Tempus AI lawsuits will likely depend on the strength of evidence discovered regarding the company’s revenue recognition practices and the adequacy of disclosures made to investors.
What Does the Tempus AI Case Reveal About Investment Risk and Due Diligence?
The Tempus AI situation serves as a reminder that companies operating in high-growth, technology-driven sectors face intense pressure to deliver impressive revenue and growth metrics to justify premium stock valuations. Artificial intelligence has become an investor obsession, with AI-focused companies commanding significant valuation multiples. When a company like Tempus AI positions itself primarily as an AI health company but realizes the vast majority of its revenue from non-AI services, a significant gap opens between market perception and underlying business reality. Investors analyzing AI company stocks should specifically parse which revenues actually derive from AI applications and which come from traditional service delivery.
The fact that Tempus AI’s AI revenue represented less than 2% of total revenue despite the company’s AI-focused positioning exemplifies this distinction. The discovery by an independent research firm rather than by the SEC or company auditors also raises questions about information asymmetry in public markets. Tempus AI’s external auditors, whose job includes evaluating whether financial statements fairly present the company’s condition, apparently did not flag the aggressive revenue recognition and related-party transaction practices as requiring disclosure or comment. This gap between auditor oversight and market detection through independent research suggests that investors cannot always rely solely on official filings and audited financial statements. Comprehensive due diligence may require engagement with independent research providers, careful scrutiny of revenue composition, and skepticism toward dramatic growth claims in emerging technology sectors where accounting practices remain contested.
Conclusion
The Tempus AI securities class action lawsuit alleged that investors were systematically misled about the company’s artificial intelligence health revenue through inflated contract values, non-binding opt-ins, questionable milestone payments, and related-party transactions. The lawsuit, filed in June 2025 following the Spruce Point Capital report and the resulting 19.23% single-day stock price collapse, targets approximately $50 million in damages on behalf of investors who purchased shares between August 6, 2024, and May 27, 2025. The case has been consolidated in federal court and represents an ongoing examination of whether Tempus AI’s financial disclosures adequately represented the true scale and health of its core AI business operations.
Investors affected by the alleged misstatements may be eligible to recover damages through the class action mechanism without incurring the substantial costs of individual litigation. As the consolidated case proceeds through discovery and toward potential settlement, it will likely generate important precedents regarding how artificial intelligence companies should account for and disclose revenue derived from AI versus non-AI operations. For current Tempus AI investors or prospective shareholders in similar AI-focused companies, the case underscores the importance of independently verifying claims about revenue composition, scrutinizing related-party transactions, and remaining appropriately skeptical of valuations based on aggressive growth projections in emerging technology sectors.